Eevia wins new customer with starting sales order for 2,1 MSEK (188 KEUR)
Eevia Health Plc (”Eevia” or ”The Company”) has received a first sales order for 188 KEUR (2,1 MSEK) from a large international ingredient company for Feno-Myrtillus® 25 organic (bilberry extracts).
Eevia received the sales order from a large international nutraceutical ingredients house, which markets ingredients on three different continents and multiple application areas. The product is Feno-Myrtillus® 25 Organic and the value of the start order is 188 KEUR (2,1 MSEK).
This first order and the new customer are the result of a lengthy engagement process. Winning this new business demonstrates Eevia’s ability to succeed in competition with other established ingredient brands.
Eevia has this bilberry extract in stock and will ship half of the order immediately and the rest within weeks. Sales from inventory have a very positive impact on cash flow from operations. This customer has the potential of very significant volumes and Eevia expects repeat orders as the businesses begin working together.
“This is an important sale and an indication of our potential. After a lengthy sales process, Eevia has established a new, larger and sophisticated customer who will increase our distribution and visibility in the market. A great win for our Team”, says Erik Eide, Commercial Director in Eevia Health.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested sustainably.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.